Psoriatic arthritis: problems and solutions (case report)

DOI: 10.47026/2413-4864-2023-4-88-99

UDC: 616.72-002.77-08-02
BBC: 55.83

Zhuravleva N.V., Aksionova A.V., Yakupova S.P., Ivanova A.V., Smirnova T.L., Kupriyanov S.V.

Psoriatic arthritis: problems and solutions (case report)

Keywords: psoriatic arthritis, psoriasis, genetically engineered biological drugs, psoriasis severity and prevalence index, recommendations of the European League against Rheumatism

The purpose of this study is to evaluate the effectiveness of therapy for psoriatic arthritis with tumor necrosis factor inhibitor α–Adalimumab. Material and methods. Retrospective and prospective analyses of psoriatic arthritis course were performed in a patient along with a comprehensive examination before and after administering therapy with a tumor necrosis factor inhibitor α-Adalimumab. The diagnosis of the patient was made on the basis of psoriatic arthritis classification criteria, the assessment of psoriatic rashes was performed according to PASI index. The laboratory study included complete blood cell count and biochemical blood tests. The patient underwent X-ray examinations of the joints and magnetic resonance imaging of the lumbosacral spine in the STIR mode. Study results. The patient's first manifestations of psoriasis were detected at the age of 12 years. At the age of 22, the patient had pain in the lower back of VAS 2-3 points, as well as enthesites in the area of the lateral epicondyle of humerus, wings of the iliac bones, trochanter major, the upper edge of the patella and tibial tuberosity, the PASI index was 17.3 points. In order to relieve pain, the patient took non-steroidal anti-inflammatory drugs. Against the background of therapy with non-steroidal anti-inflammatory drugs, the intensity of pain in the lower back decreased, but enthesites persisted. At the age of 35, the patient was diagnosed with psoriatic arthritis, activity III, stage II, dactylitis, enthesites, PASI index 38.5 points; right-sided active sacroiliitis, ASDAS ESR index activity was 3.92 points, joint functional insufficiency of the 2^nd degree. Methotrexate therapy was prescribed. There was no positive dynamics against the background of treatment, in connection with this, therapy with genetically engineered biological drugs was initiated. We observed positive dynamics in the clinical course of psoriatic arthritis when Adalimumab was included in the treatment: after the 2^nd week of treatment, the articular syndrome subsided, joint pain decreased when evaluated on a scale of 2-3 points, the number of psoriatic plaques on the trunk and limbs decreased as well, the index of psoriatic rashes was 5.3 points. After 8 weeks from the start of therapy with Adalimumab, regression of pathological skin rashes was noted, the index of psoriatic rashes was 0 points. Conclusions. Therapy with Adalimumab in the patient resulted in regression of psoriatic manifestations on the skin, suppression of psoriatic arthritis activity. The study showed the clinical effectiveness of a genetically engineered biological drug – Adalimumab in achieving persistent clinical remission of psoriatic arthritis.

References

Addimanda O., Possemato N., Caruso A. et al. The role of tumor necrosis factor-α blockers in psoriatic disease. Therapeutic options in psoriatic arthritis. The journal of rheumatology Supplement, 2015, vol. 93, pp. 73–78. DOI: 10.3899/jrheum.150642.
Burlando M., Cozzani E., Schiavetti I. et al. The STRIPP questionnaire (Screening Tool for Rheumatologic Investigation in Psoriatic Patients) as a new tool for the diagnosis of early psoriatic arthritis. Giornale italiano di dermatologia e venereologia, 2020, vol. 155, no. 3, pp. 294–298. DOI: 10.23736/S0392-17.05745-5.
Coates L.C., Kavanaugh A., Mease P.J. et al. Group for research and assessment of psoriasis and psoriatic arthritis, 2015. Treatment recommendations for psoriatic arthritis. Arthritis and rheumatology, 2016, vol. 68, no. 5, pp. 1060–1071. DOI: 10.1002/art.39573.
Gorlier C., Orbai A.M., Puyraimond-Zemmour D. et al. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Annals of the rheumatic diseases, 2019, vol. 78, no. 2, pp. 201–208. DOI: 10.1136/annrheumdis-2018-214140.
Gossec L., de Wit M., Kiltz U. et al. EULAR PsAID Taskforce. A patientderived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the rheumatic diseases, 2014, vol. 73, no. 6, pp. 1012–1019. DOI: 10.1136/annrheumdis-2014-205207.
Gossec L., Smolen J.S., Ramiro S. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the rheumatic diseases, 2016, vol. 75, no. 3, pp. 499–510. DOI: 10.1136/annrheumdis-2015-208337.
Gossec L., Baraliakos X., Kerschbaumer A. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the rheumatic diseases, 2020, vol. 79, no. 6, pp. 700–712. DOI: 10.1136/annrheumdis-2020-217159.
Haroon M., Winchester R., Giles J.T. et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Annals of the rheumatic diseases, 2016, vol. 75, no. 1, pp. 155–162. DOI: 10.1136/annrheumdis-2014-205461.
Iragorri N., Hazlewood G., Manns B. et al. Psoriatic arthritis screening: a systematic review and meta-analysis. Rheumatology (Oxford), 2019, vol. 58, no. 4, pp. 692–707. DOI: 10.1093/rheumatology/key314.
Kaine J., Song X., Kim G. et al. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative claims data. Journal of managet care and specialty pharmacy, 2019, vol. 25, no. 1, pp. 122–132. DOI: 10.18553/jmcp.2018.17421.
Katsevman G.A., Mariscal G., Barrios C. et al. Efficacy and safety of anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A Meta-analysis. Monoclonal antibodies in Immunodiagnosis and immunotherapy, 2020, vol. 39, no. 5, pp. 160–166. DOI: 10.1089/mab.2020.0022.
Kavanaugh A., Mease P.J., Gomez-Reino J.J. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebocontrolled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Annals of the rheumatic diseases, 2014, vol. 73, no. 6, pp. 1020–1026. DOI: 10.1136/annrheumdis-2013-205056.
Stuart P.E., Nair R.P., Tsoi L.C. et al. Genome-wide association analysis of psoriatic prthritis and cutaneous psoriasis reveals differences in their genetic architecture. American journal of human genetic, 2015, vol. 97, no. 6, pp. 816–836. DOI: 10.1016/j.ajhg.2015.10.019.
Tom B.D., Chandran V., Farewell V.T. et al. Validation of the Toronto Psoriatic Arthritis Screen version 2 (ToPAS 2). The journal of rheumatology, 2015, vol. 42, no. 5, pp. 841–846. DOI: 10.3899/jrheum.140857.
Tom S., Zhong Y., Cook R. et al. Development of a preliminary ultrasonographic enthesitis score in psoriatic arthritis – GRAPPA ultrasound working group. The Journal of rheumatology, 2019, vol. 46, no. 4, pp. 384–390. DOI: 10.3899/jrheum.171465.
Yaghoobi R., Soghrati M., Pazyar N., Parvin N. Investigating the effect of 1% curcumin gel and placebo on patients with plaque psoriasis. International Journal of Life science and Pharma Research (IJLPR), 2018, vol. 8, no. 4, pp. 48–57. DOI: http://dx.doi.org/10.22376/ijpbs/lpr.2018.8.4.L48-57.
Yiu Z.Z, Warren R.B. Ustekinumab for the treatment of psoriasis: an evidence update. Seminars in cutaneous medicine and surgery, 2018, vol. 37, no. 3, pp. 143–147. DOI: 10.12788/j.sder.2018.040.

About authors

Zhuravleva Nadezhda V.: Candidate of Medical Sciences, Associate Professor, Department of Internal Diseases, Chuvash State University; Rheumatologist, Central City Hospital, Russia, Cheboksary (zhuravlevanv@mail.ru; ORCID: https://orcid.org/0000-0001-6470-7724)

Aksionova Angelina V.: Doctor of Medical Sciences, Professor, Department of Faculty Therapy named after Academician A.I. Nesterov, N.I. Pirogov Russian National Research Medical University, Russia, Moscow (aksyonova-av@mail.ru; ORCID: https://orcid.org/0000-0002-4259-3807)

Yakupova Svetlana P.: Candidate of Medical Sciences, Associate Professor, Department of Hospital Therapy, Kazan State Medical University; Chief Freelance Rheumatologist, Ministry of Health of the Republic of Tatarstan, Russia, Kazan (yakupovaSP@mail.ru; ORCID: https://orcid.org/0000-0002-8590-4839)

Ivanova Anastasia V.: Chief Rheumatologist, Ministry of Health of the Chuvash Republic; Rheumatologist, Republican Clinical Hospital, Russia, Cheboksary (nastya_arh83@mail.ru; ORCID: https://orcid.org/0000-0002-0553-3135)

Smirnova Tatyana L.: Candidate of Medical Sciences, Associate Professor, Department of Obstetrics and Gynecology, Chuvash State University, Russia, Cheboksary (tlsmr@mail.ru; ORCID: https://orcid.org/0000-0002-8224-1515)

Kupriyanov Sergey V.: Doctor of Medical Sciences, Professor, Head of the Department of Normal and Pathological Physiology, Chuvash State University, Russia, Cheboksary (kuper-SV@yandex.ru; ORCID: https://orcid.org/0000-0002-5272-7397)

Article link

Zhuravleva N.V., Aksionova A.V., Yakupova S.P., Ivanova A.V., Smirnova T.L., Kupriyanov S.V. Psoriatic arthritis: problems and solutions (case report) [Electronic resource] // Acta medica Eurasica. – 2023. – №4. P. 88-99. – URL: https://acta-medica-eurasica.ru/en/single/2023/4/9/. DOI: 10.47026/2413-4864-2023-4-88-99.

Single article

Zhuravleva N.V., Aksionova A.V., Yakupova S.P., Ivanova A.V., Smirnova T.L., Kupriyanov S.V.